Comprehensive lipidomic dataset reveals melittin's impact on lipid metabolism in triple-negative breast cancer, suggesting therapeutic potential.
Melittin, the principal active peptide of bee venom, exhibits potent cytotoxicity against cancer cells. However, its lipid-level mechanisms remain unclear. Here, we present the first untargeted lipidomic dataset that reveals melittin-induced lipid remodeling in triple-negative breast cancer (TNBC) cells (MDA-MB-231). Cells were exposed to 4 μg/mL of melittin for 15 min, and lipid extracts were analyzed by employing high-resolution LC–MS/MS in both ion modes. Data were processed with XCMS and metaX for peak extraction, normalization, and metabolite annotation, followed by multivariate and KEGG pathway analyses. The results highlight significant alterations in phospholipids, sphingolipids, and acylglycerols, indicative of melittin-mediated disruption of membrane integrity and lipid metabolism. All raw and processed data are publicly accessible at NGDC (accession number PRJCA048975). This dataset not only serves as a comprehensive resource for investigating lipid-based mechanisms underlying melittin’s anticancer effects but also supports its potential in lipid-targeted therapeutic strategies for TNBC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: